Search

Action Bladder Cancer UK: Understanding Bladder Cancer and the latest developments. A Nurses Education Day

This Education Day aims to provide nurses with up-to-date knowledge on bladder cancer treatments and the newest developments. Urology nurses and cancer nurses across the UK will have the opportunity to network and share their experiences and expertise. This event is also open to nurses who wish to extend their knowledge of bladder cancer and who may be working in other areas of urology or cancer care.

The Royal Marsden Fundamentals of Bladder Cancer for Nurses and AHPs

Introducing the fundamentals of bladder cancer; including signs and symptoms, diagnosis, types of disease and management. The day will feature the role of the nurse at different stages of the pathway. We have expert clinical speakers to deliver the session along with sessions run by our expert patients.

RSM (Royal Society of Medicine) Support and survivorship in urological cancer management: A multidisciplinary update

Building on last year's Urology Section Cancer Day, this event will feature internationally renowned speakers from across the urology MDT including urologists, radiologists, oncologists, pathologists and specialist nurses. In doing so, we will provide a unique holistic insight into the management of patients with urological cancers relevant to those involved in caring for these patients and those studying for the FRCS(Urol) exam.

EAU (European Association of Urology) Masterclass on Focal therapy for localised prostate cancer

Focal Therapy (FT) is a promising treatment option aimed at improving the management of localised prostate cancer. This masterclass will provide you with an extensive review of the rationale for FT, the patient selection modalities and the available energy sources (HIFU, Cryo, IRE, Laser, Brachytherapy). Gain further knowledge and better understand the FT benefits.

APCCC (Advanced Prostate Cancer Consensus Conference) Diagnostics 2025

The diagnostic abilities for assessing prostate cancer patients have significantly evolved in the last years. Ranging from advanced imaging modalities for detection, new innovative liquid and tissue based biomarkers as well as the recent introduction of PSMA PET imaging have significantly advanced the field, challenging some of the old grounds of truth.